Drugs / HBV-MPL vaccine Formulation B
last change May 1999 re-read 2 minutes ago

HBV-MPL vaccine Formulation B

Vaccine

Developed for
hepatitis B virus infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00697775 Mar 1998 → May 1999 hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HBV-MPL vaccine Formulation B ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697775
Modality Vaccine “HBV-MPL vaccine Formulation B” NCT00697775
Route Intramuscular “2-dose intramuscular injection” NCT00697775